Skip to main content
. 2022 May 9;2(5):330–341. doi: 10.1158/2767-9764.CRC-22-0083

FIGURE 2.

FIGURE 2

BCMA is expressed at low levels on primary CLL cells and can be slightly enhanced by γ-secretase inhibition. A, CLL cells were cultured and basal levels of BCMA were assessed by flow cytometry and compared with isotype controls (n = 25). B, Assessment of BCMA mRNA relative to GAPDH control by qPCR after primary CLL samples were treated without or with 100 nmol/L γ-secretase inhibitor for 24 hours (n = 9). C, CLL cells were treated for 24 or 48 hours with 0 or 100 nmol/L γ-secretase inhibitor and BCMA was assessed by flow cytometry. Values are represented as fold increase compared with medium control (n = 12–28). D, Basal levels of BCMA compared with isotype control among patients with CLL with mutated or unmutated IgVH (n = 4–10). E, Fold increase of BCMA after 24–48 hours treatment with 100 nmol/L γ-secretase inhibitor compared with medium control among patients with CLL with mutated or unmutated IgVH (n = 5–13). F, Assessment of sBCMA by ELISA in supernatants of B-cell malignancy cell lines after treatment with 100 nmol/L γ-secretase inhibitor or medium control for 24–48 hours (n = 4–12). The P value was calculated by Wilcoxon test (A and B), Mann–Whitney test (B–D) or paired t test (E and F). Data are presented as mean ± SD. *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001.